MindBio Therapeutics Corp. reported that dosing is progressing well in its Phase 2a Depression trial using MB22001 (MindBio's proprietary titratable form of LSD for at home Microdosing). To date, twelve participants have started their dosing regimen and a few participants have now successfully completed their entire treatment.

Justin Hanka, Chief Executive Officer of MindBio Therapeutics discusses the progress of this clinical trial, the hope for sufferers of depression and the primary end points that would deem the trial of MB22001 in depressed patients a success. This landmark Phase 2a clinical trial has obtained regulatory approvals for at-home use of LSD in patients with Major Depressive Disorder. At-home use is crucial for testing and modelling the safety and efficacy of psychedelic medicines within the community, as MindBio works towards having these life-saving medicines approved.

MindBio's landmark Phase 1 LSD-Microdosing clinical trial completed in 2022 showed no serious adverse events, and participants in the LSD-Microdosing treatment group reported statistically significant increases in feelings of happiness, social connectivity, wellness, creativity, and energy compared to the placebo group. MindBio's Phase 2a clinical trial in 20 patients with Major Depressive Disorder is an open label trial that will look for clinically significant improvements in depression rating scores using a global standard for measuring the severity of depression, the MADRS (Montgomery Asberg Depression Rating Scale). MB22001 is being administered in titratable microdoses to clinical trial participants.

At the end of the trials, the primary end point for success is an improvement in the MADRS.